Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T)

Trial Profile

Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Letrozole (Primary)
  • Indications Endometrial cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
    • 23 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top